Overall survival of patients was significantly longer in PD-L1 combined positive score≥10% subgroup.227 The US FDA has approved individual immunohistochemistry (IHC)-based assays for each drug, respectively Dako 22C3, Dako 28-8, Ventana SP142 and Ventana SP263.228 The positive rate of PD-1 expression in NSCLC cells is similar to antibodies 22C3, 28-8 and SP263 detection, but still, needs clinical validation.229,230 General commercial assay with optimum cutoff point applicable to multiple tumours is a hot spot for detection development. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.